Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Female Sexual Dysfunction Drugs
While men have had Viagra, Cialis, and Levitra to address their sexual dysfunction issues for about a decade, finding a solution for women’s woes has been more complicated. The market for female sexual dysfunction (FSD) drugs is believed larger than the market for male sexual dysfunction treatments, yet despite this no FDA-approved treatments for FSD exist—though several drug developers are closer than ever to changing that. Once approved, how much of a rise do you think they’ll get in sales compared to ED drugs?